Multi-omics approaches for biomarker discovery in early ovarian cancer diagnosis
Yinan Xiao,
Meiyu Bi,
Hongyan Guo,
Mo Li
Affiliations
Yinan Xiao
Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Peking University Third Hospital, Beijing 10091, China; National Clinical Research Center for Obstetrics and Gynecology, Peking University Third Hospital, Beijing 10091, China; Key Laboratory of Assisted Reproduction, Ministry of Education, Peking University, Beijing 100191, China; Beijing Key Laboratory of Reproductive Endocrinology and Assisted Reproductive Technology, Peking University Third Hospital, Beijing 10091, China
Meiyu Bi
Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Peking University Third Hospital, Beijing 10091, China; National Clinical Research Center for Obstetrics and Gynecology, Peking University Third Hospital, Beijing 10091, China; Key Laboratory of Assisted Reproduction, Ministry of Education, Peking University, Beijing 100191, China; Beijing Key Laboratory of Reproductive Endocrinology and Assisted Reproductive Technology, Peking University Third Hospital, Beijing 10091, China
Hongyan Guo
National Clinical Research Center for Obstetrics and Gynecology, Peking University Third Hospital, Beijing 10091, China
Mo Li
Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Peking University Third Hospital, Beijing 10091, China; National Clinical Research Center for Obstetrics and Gynecology, Peking University Third Hospital, Beijing 10091, China; Key Laboratory of Assisted Reproduction, Ministry of Education, Peking University, Beijing 100191, China; Beijing Key Laboratory of Reproductive Endocrinology and Assisted Reproductive Technology, Peking University Third Hospital, Beijing 10091, China; Corresponding author at: Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Peking University Third Hospital, Beijing 10091, China.
Summary: Ovarian cancer (OC) is a heterogeneous disease with the highest mortality rate and the poorest prognosis among gynecological malignancies. Because of the absence of specific early symptoms, most OC patients are often diagnosed at late stages. Thus, improved biomarkers of OC for use in research and clinical practice are urgently needed. The last decade has seen increasingly rapid advances in sequencing and biotechnological methodologies. Consequently, multiple omics technologies, including genomic/transcriptomic sequencings and proteomic/metabolomic mass spectra, have been widely applied to analyze tissue- and liquid-derived samples from OC patients. The integration of multi-omics data has increased our knowledge of the disease and identified valuable OC biomarkers. In this review, we summarize the recent advances and perspectives in the use of multi-omics technologies in OC research and highlight potential applications of multi-omics for identifying novel biomarkers and improving clinical assessments.
